Velakast Tablet
Rx RequiredSalt Composition: Velpatasvir and Sofosbuvir
Expiry Date: 01/2028
Price on Request
Inclusive of all taxes
28 tablet
About The Product
Hepatitis C
Velakast Tablet is a combination of Sofosbuvir and Velpatasvir, used to treat chronic (long-lasting) Hepatitis C Virus in adults. It slows the multiplication process of the virus and helps the immune system fight against the infection. Velakast is a fixed-dose tablet for oral administration. It is advised to take the dose every day at the same time. It may help your liver to recover.
Uses
Treatment of Chronic hepatitis C virus (HCV) infection
Side Effects
Velakast tablets may cause certain side effects. If side effects occur after administration or last longer than usual, contact your healthcare professional.
Nausea
Vomiting
Insomnia
Weight loss
Headache
Tiredness
Fatigue
Diarrhea
Urine infection
Dark colored urine
Dosage and Administration
Your healthcare provider will prescribe you the dose according to the severity of the disease. Take the dose exactly as prescribed, without any alteration/manipulation.
Please contact your healthcare provider immediately in case of an overdose.
Safety Advice
It is advisable not to consume alcohol while taking this medicine.
Do not take Velakast tablets without consulting the doctor, in case of pregnancy.
Without a doctor's consultation, do not take this medicine if you're breastfeeding.
It is advisable not to drive or operate heavy machinery, you may feel dizzy as one of the side effects of the medicine.
Do not take Velakast tablets without a doctor's consultation in case of kidney problems.
Share your medical history with the doctor in case of liver disease before taking this medicine.
Missed Doses
- If you miss a dose of Velakast tablets , take it as soon as you remember.
- If it is already the time for the next dose, do not take 2 doses.
- Do not double the doses to catch up.
FAQs
Velakast is a combination of Sofosbuvir and Velpatasvir, used to treat chronic (long-lasting)
Hepatitis C Virus in adults.
Reference
Efficacy and safety of direct‑acting antiviral regimen for patients with hepatitis C virus genotype 2: A systematic review and meta‑analysis. (2024). BMC Gastroenterology, 24, Article 34? BioMed Central Sofosbuvir/velpatasvir in decompensated cirrhotic patients with genotype 1 and 2: A prospective multicenter real-world study in India. (2024). Journal of Clinical and Experimental Hepatology. PubMed+1jcehepatology.com+1
Sofosbuvir/velpatasvir/voxilaprevir for Hepatitis C virus retreatment in difficult‑to‑treat patients: A real‑life observational study from India. (2023). Journal of Clinical and Experimental Hepatology Sofosbuvir–velpatasvir single‑tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India. (2023). BMC Medicine / multicenter Indian cohort. PMC
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
.png&w=48&q=75 "Cart"){kind=small}
9655.png&w=48&q=75 "Home"){kind=small}
